Cancer Treatment Centers of America ATLANTA CANCER REGISTRY Annual Report
CANCER COMMITTEE Chairman s Report On behalf of the Cancer Committee a multidisciplinary team of boardcertified physicians and health care professionals it is my privilege to share clinical excellence highlights over the last year as we continue to focus on quality, safety and value-based health care delivery. In calendar year 2017, Cancer Treatment Centers of America (CTCA), Atlanta saw a total of 2,801 cases. We set out to further expand our clinical services while continuing to deliver personalized, compassionate and integrative cancer care to even more patients. The data in this report reflects our 2017 initiatives and a few highlights of our accomplishments. The following are some focus areas we have been working on at CTCA Atlanta. Sean Cavanaugh, MD Chairman, Cancer Committee Chief, Radiation Oncology Director, Genitourinary Cancer Center CTCA Atlanta Growing our clinical staff: adding on Elizabeth Min Hui Kim, MD, MPH, FACS as a Breast Surgical Oncologist and Director of the Breast Cancer Institute Developing a robust Neuroendocrine Tumor (NET) Clinical Program, including being the first center in Georgia to use Peptide Receptor Radionuclide Therapy (PRRT) to treat the disease and one of the first in the state to use NETSPOT (gallium Ga 68 dotatate) to diagnose it Improving our survivorship program to help patients transition from active treatment to surveillance Creating more psychosocial distress screenings by implementing an education program regarding suicide risk assessment and working on psychoeducation related to symptom management for sleep and fatigue Helping meet the needs of our local community by offering breast cancer screenings and breast and lung cancer educational sessions (learn more about our 2017 events on page 10) 2 CTCA Atlanta 2018 CANCER REGISTRY ANNUAL REPORT
Continuing our journey to Magnet Excellence while increasing the number of chemotherapy competent nurses and Oncology Certified Nursing (OCN) nurses Renewing our American College of Radiology (ACR) accreditation for Radiation Oncology and being recognized by the American Cancer Society (ACS) with a Breast Cancer Strides award Striving to provide high-quality, state-of-the-art oncologic services and supportive care with an emphasis on the patient We look forward to sharing more clinical advances and serving more patients in the year to come. Sincerely, Sean Cavanaugh, MD CONTENTS 4 Cancer Registry Report 5 Cancer Conference Summary 6 2017 Primary Sites 9 Patients by Region 10 Screening and Prevention Programs 11 Accreditations and Certifications Cancer Committee Chairman Chief, Radiation Oncology Director, Genitourinary Center for Advanced Oncology The information presented throughout the 2018 Cancer Registry Annual Report reflects the data collected from January 1 to December 31, 2017 unless otherwise noted. 3 CTCA Atlanta 2018 CANCER REGISTRY ANNUAL REPORT
CANCER REGISTRY Report The Cancer Registry team in Atlanta, Georgia has entered 14,716 cases into the database since January 1, 2013. The Atlanta Cancer Registry maintains a data system designed for collection, management and analysis of data on individuals diagnosed with cancer. The Cancer Registry has entered a total of 14,716 cases (analytic and non-analytic) into the Cancer Registry database since January 1, 2013. During 2017, a total of 2,801 cases were accessioned into the Cancer Registry database. Of these cases, 1,305 were analytic and 1,496 were non-analytic. Of these, 1,227 were male and 1,574 were female. The Cancer Registry professionals are responsible for collecting and recording the most complete and accurate cancer data possible with continuous quality improvement review by the Cancer Committee physicians. The registry staff performs the daily functions of the Tumor Registry. They ensure data accuracy with continuous quality improvement reviews by the Cancer Committee, which analyzes patient outcomes and can make evidence-informed, clinical decisions. Cancer Registry Activities at CTCA Atlanta Responded to requests for data Submitted all required cases error free on initial submission to the National Cancer Database Participated in and attended the Georgia Cancer Registrars Association Educational Fall Workshop Submitted all required cases to the Georgia Central Cancer Registry Attended the National Cancer Registrars Association Educational Conference in Washington, DC Coordinated and attended monthly Cancer Committee meetings Assisted with coordination and attendance of quarterly National Accreditation Program for Breast Centers (NAPBC) leadership meetings Coordinated and attended weekly Thoracic, Breast and General Cancer Conferences Participated in North American Association of Central Cancer Registries (NAACCR) seminars Maintained membership with the National Cancer Registrars Association Maintained membership with the Georgia Cancer Registrars Association Played an integral role in the completion of the annual report 4 CTCA Atlanta 2018 CANCER REGISTRY ANNUAL REPORT
PRIMARY SITE # OF CASES Ill-Defined Site 9 Breast 33 Lung 94 2017 CANCER CONFERENCE Summary During 2017, a multidisciplinary team of physicians and clinicians from departments including medical oncology, radiation oncology, radiology, pathology and surgery, attended 144 disease-specific cancer conferences focusing on breast, lung and head/neck cases, as well as general cancer conferences. The nursing and ancillary staff also attended these conferences to ensure comprehensive representation. Together, they reviewed cases in detail and discussed staging, prognostic indicators, national guidelines, plans for appropriate diagnostic studies, therapies and clinical trials. These prospective, patient-oriented and multidisciplinary physician care planning meetings provide free consultation to our patients and education for the medical and hospital staff. Of the 421 cases presented, 98 percent were prospective patient presentations. Lymphoma 2 Head & Neck 28 GYN 33 Colorectal 85 Genitourinary 20 Endocrine 2 Soft Tissue 1 Unknown Primary 20 Melanoma/Skin 12 Gastrointestinal 69 Prostate 6 CNS/Brain 1 Blood/Bone Marrow 6 Total 421 5 CTCA Atlanta 2018 CANCER REGISTRY ANNUAL REPORT
Primary Sites Summary by Body System, Sex, Class and Best CS/AJCC Stage Report Sex Class of Case Status Stage Distribution - Analytic Cases Only Primary Site Total (%) M F Analy 1 NA 2 Alive Exp Stg 0 Stg I Stg II Stg III Stg IV 88 Unk Blank ORAL CAVITY & PHARYNX 71 (2.5%) 56 15 36 35 61 10 0 7 1 3 23 0 2 0 Tongue 27 (1.0%) 21 6 16 11 24 3 0 4 0 1 11 0 0 0 Salivary Glands 5 (0.2%) 4 1 2 3 5 0 0 1 0 0 1 0 0 0 Floor of Mouth 2 (0.1%) 2 0 1 1 1 1 0 1 0 0 0 0 0 0 Gum & Other Mouth 8 (0.3%) 5 3 3 5 5 3 0 0 0 1 2 0 0 0 Nasopharynx 2 (0.1%) 2 0 0 2 2 0 0 0 0 0 0 0 0 0 Tonsil 22 (0.8%) 19 3 11 11 20 2 0 1 1 1 7 0 1 0 Oropharynx 3 (0.1%) 2 1 2 1 3 0 0 0 0 0 1 0 1 0 Hypopharynx 2 (0.1%) 1 1 1 1 1 1 0 0 0 0 1 0 0 0 DIGESTIVE SYSTEM 695 (24.8%) 393 302 299 396 452 243 0 16 37 53 187 3 3 0 Esophagus 30 (1.1%) 25 5 12 18 16 14 0 0 3 3 6 0 0 0 Stomach 48 (1.7%) 31 17 30 18 30 18 0 3 6 3 17 0 1 0 Small Intestine 35 (1.2%) 16 19 9 26 27 8 0 1 0 1 7 0 0 0 Colon Excluding Rectum 214 (7.6%) 112 102 70 144 157 57 0 3 11 18 38 0 0 0 Cecum 36 17 19 19 17 30 6 0 2 1 6 10 0 0 0 Appendix 11 5 6 4 7 7 4 0 0 0 0 4 0 0 0 Ascending Colon 41 22 19 11 30 30 11 0 1 2 2 6 0 0 0 Hepatic Flexure 2 0 2 0 2 1 1 0 0 0 0 0 0 0 0 Transverse Colon 16 10 6 7 9 9 7 0 0 2 1 4 0 0 0 Splenic Flexure 7 4 3 3 4 6 1 0 0 1 0 2 0 0 0 Descending Colon 11 6 5 4 7 9 2 0 0 1 2 1 0 0 0 Sigmoid Colon 57 31 26 16 41 42 15 0 0 4 6 6 0 0 0 Large Intestine, NOS 33 17 16 6 27 23 10 0 0 0 1 5 0 0 0 Rectum & Rectosigmoid 103 (3.7%) 58 45 41 62 90 13 0 5 4 15 17 0 0 0 Rectosigmoid Junction 20 13 7 7 13 15 5 0 0 0 3 4 0 0 0 Rectum 83 45 38 34 49 75 8 0 5 4 12 13 0 0 0 Anus, Anal Canal & Anorectum 7 (0.2%) 2 5 3 4 6 1 0 0 0 2 1 0 0 0 Liver & Intrahepatic Bile Duct 46 (1.6%) 33 13 20 26 23 23 0 2 1 1 13 2 1 0 Liver 39 30 9 17 22 20 19 0 2 1 1 10 2 1 0 Intrahepatic Bile Duct 7 3 4 3 4 3 4 0 0 0 0 3 0 0 0 Gallbladder 9 (0.3%) 1 8 4 5 5 4 0 0 0 1 3 0 0 0 Other Biliary 7 (0.2%) 5 2 3 4 4 3 0 0 0 1 2 0 0 0 Pancreas 191 (6.8%) 109 82 105 86 91 100 0 2 12 8 82 0 1 0 Retroperitoneum 1 (0.0%) 0 1 0 1 0 1 0 0 0 0 0 0 0 0 Peritoneum, Omentum & Mesentery 2 (0.1%) 0 2 1 1 1 1 0 0 0 0 1 0 0 0 Other Digestive Organs 2 (0.1%) 1 1 1 1 2 0 0 0 0 0 0 1 0 0 RESPIRATORY SYSTEM 318 (11.4%) 158 160 153 165 214 104 0 13 12 49 76 3 0 0 Nose, Nasal Cavity & Middle Ear 6 (0.2%) 3 3 2 4 6 0 0 1 0 0 1 0 0 0 Larynx 17 (0.6%) 13 4 11 6 14 3 0 3 1 4 3 0 0 0 6 CTCA Atlanta 2018 CANCER REGISTRY ANNUAL REPORT
Primary Sites Summary by Body System, Sex, Class and Best CS/AJCC Stage Report Sex Class of Case Status Stage Distribution - Analytic Cases Only Primary Site Total (%) M F Analy 1 NA 2 Alive Exp Stg 0 Stg I Stg II Stg III Stg IV 88 Unk Blank Lung & Bronchus 292 (10.4%) 139 153 138 154 193 99 0 9 11 45 72 1 0 0 Trachea, Mediastinum & Other Respiratory Organs 3 (0.1%) 3 0 2 1 1 2 0 0 0 0 0 2 0 0 BONES & JOINTS 2 (0.1%) 1 1 0 2 2 0 0 0 0 0 0 0 0 0 SOFT TISSUE 18 (0.6%) 12 6 8 10 16 2 0 3 0 3 1 1 0 0 SKIN EXCLUDING BASAL & SQUAMOUS 38 (1.4%) 21 17 15 23 31 7 1 3 2 4 3 1 1 0 Melanoma -- Skin 34 (1.2%) 19 15 13 21 28 6 1 2 2 4 3 0 1 0 Other Non-Epithelial Skin 4 (0.1%) 2 2 2 2 3 1 0 1 0 0 0 1 0 0 BASAL & SQUAMOUS SKIN 9 (0.3%) 4 5 0 9 8 1 0 0 0 0 0 0 0 0 BREAST 674 (24.1%) 12 662 335 339 611 63 33 111 105 53 30 0 3 0 FEMALE GENITAL SYSTEM 252 (9.0%) 0 252 83 169 187 65 1 23 5 21 31 2 0 0 Cervix Uteri 50 (1.8%) 0 50 17 33 40 10 1 2 2 5 7 0 0 0 Corpus & Uterus, NOS 91 (3.2%) 0 91 27 64 59 32 0 11 1 3 11 1 0 0 Corpus Uteri 79 0 79 23 56 54 25 0 11 1 3 7 1 0 0 Uterus, NOS 12 0 12 4 8 5 7 0 0 0 0 4 0 0 0 Ovary 83 (3.0%) 0 83 28 55 63 20 0 6 0 12 10 0 0 0 Vagina 8 (0.3%) 0 8 4 4 8 0 0 1 1 1 1 0 0 0 Vulva 8 (0.3%) 0 8 3 5 7 1 0 2 0 0 1 0 0 0 Other Female Genital Organs 12 (0.4%) 0 12 4 8 10 2 0 1 1 0 1 1 0 0 MALE GENITAL SYSTEM 354 (12.6%) 354 0 196 158 338 16 0 31 109 23 33 0 0 0 Prostate 351 (12.5%) 351 0 193 158 335 16 0 30 108 22 33 0 0 0 Testis 3 (0.1%) 3 0 3 0 3 0 0 1 1 1 0 0 0 0 URINARY SYSTEM 179 (6.4%) 127 52 83 96 157 22 5 23 10 16 27 1 1 0 Urinary Bladder 78 (2.8%) 60 18 32 46 67 11 5 4 6 6 11 0 0 0 Kidney & Renal Pelvis 97 (3.5%) 66 31 49 48 87 10 0 19 4 9 15 1 1 0 Ureter 1 (0.0%) 0 1 1 0 1 0 0 0 0 0 1 0 0 0 Other Urinary Organs 3 (0.1%) 1 2 1 2 2 1 0 0 0 1 0 0 0 0 EYE & ORBIT 1 (0.0%) 1 0 0 1 1 0 0 0 0 0 0 0 0 0 BRAIN & OTHER NERVOUS SYSTEM 2 (0.1%) 2 0 1 1 1 1 0 0 0 0 0 1 0 0 Brain 1 (0.0%) 1 0 0 1 0 1 0 0 0 0 0 0 0 0 Cranial Nerves Other Nervous System 1 (0.0%) 1 0 1 0 1 0 0 0 0 0 0 1 0 0 ENDOCRINE SYSTEM 28 (1.0%) 14 14 13 15 27 1 0 5 2 0 1 4 1 0 Thyroid 17 (0.6%) 8 9 8 9 17 0 0 5 1 0 1 0 1 0 Other Endocrine including Thymus 11 (0.4%) 6 5 5 6 10 1 0 0 1 0 0 4 0 0 LYMPHOMA 79 (2.8%) 38 41 46 33 75 4 0 7 14 5 20 0 0 0 Hodgkin Lymphoma 17 (0.6%) 9 8 12 5 17 0 0 0 3 1 8 0 0 0 Non-Hodgkin Lymphoma 62 (2.2%) 29 33 34 28 58 4 0 7 11 4 12 0 0 0 NHL - Nodal 46 24 22 26 20 43 3 0 4 9 3 10 0 0 0 NHL - Extranodal 16 5 11 8 8 15 1 0 3 2 1 2 0 0 0 7 CTCA Atlanta 2018 CANCER REGISTRY ANNUAL REPORT
Primary Sites Summary by Body System, Sex, Class and Best CS/AJCC Stage Report Sex Class of Case Status Stage Distribution - Analytic Cases Only Primary Site Total (%) M F Analy 1 NA 2 Alive Exp Stg 0 Stg I Stg II Stg III Stg IV 88 Unk Blank MYELOMA 21 (0.7%) 8 13 11 10 19 2 0 0 0 0 0 11 0 0 LEUKEMIA 17 (0.6%) 9 8 9 8 17 0 0 0 0 0 0 9 0 0 Lymphocytic Leukemia 9 (0.3%) 7 2 5 4 9 0 0 0 0 0 0 5 0 0 Chronic Lymphocytic Leukemia 8 6 2 4 4 8 0 0 0 0 0 0 4 0 0 Other Lymphocytic Leukemia 1 1 0 1 0 1 0 0 0 0 0 0 1 0 0 Myeloid & Monocytic Leukemia 6 (0.2%) 1 5 2 4 6 0 0 0 0 0 0 2 0 0 Acute Myeloid Leukemia 1 0 1 0 1 1 0 0 0 0 0 0 0 0 0 Chronic Myeloid Leukemia 4 1 3 2 2 4 0 0 0 0 0 0 2 0 0 Other Myeloid/Monocytic Leukemia 1 0 1 0 1 1 0 0 0 0 0 0 0 0 0 Other Leukemia 2 (0.1%) 1 1 2 0 2 0 0 0 0 0 0 2 0 0 MESOTHELIOMA 2 (0.1%) 1 1 0 2 1 1 0 0 0 0 0 0 0 0 MISCELLANEOUS 41 (1.5%) 16 25 17 24 23 18 0 0 0 0 0 17 0 0 TOTAL 2,801 1,227 1,574 1,305 1,496 2,241 560 40 242 297 230 432 53 11 0 1 Analytic patients are those who are diagnosed and/or receive all or part of their first course of cancer treatment at CTCA. 2 Non-analytic patients are those who receive subsequent cancer treatment at CTCA due to progressive or recurrent disease. 8 CTCA Atlanta 2018 CANCER REGISTRY ANNUAL REPORT
CTCA Atlanta Patients BY REGION 27 MIDWEST 245 NORTHEAST 14 WEST 223 SOUTHWEST 2,254 SOUTHEAST 2,801 9 Total Cases in 2017 by Region for CTCA Atlanta CTCA Atlanta 2018 C A N C E R R E G I S T R Y A N N UA L R E P O R T 19 19 OTHER COUNTRIES VIRGIN ISLANDS
Cancer Prevention and Screening Programs AT CTCA ATLANTA 2 prevention events hosted in 2017 43 women screened for breast cancer Lung and Breast Cancer Awareness and Prevention To address the identified needs of the local Coweta County community (based on a triennial Community Health Needs Assessment (CHNA) conducted in early 2015), CTCA Atlanta hosted two events for the community focused on breast cancer screenings and lung cancer prevention education in 2017. The defined community represents both the largest number of patients served at CTCA Atlanta and the hospital s physical footprint. The results of the CHNA revealed lung and breast cancer are among the top cancer-related causes of death within the community. Throughout Breast Cancer Awareness Month in October, CTCA Atlanta provided screening mammograms to members of the community, with a focus on early detection and prevention. The screenings included a digital mammogram featuring tomosynthesis and educational information on the importance of breast cancer awareness and early detection. Forty-three (43) local women participated in the screenings, with two (2) requiring follow-up. In November, in recognition of Lung Cancer Awareness Month, CTCA Atlanta hosted a Dinner and Discussion with the Doctor featuring Patricia Rich, MD, Medical Oncology Director of the Lung Cancer Institute and Vice Chief of Staff at Atlanta. Dr. Rich provided an educational presentation to approximately 30 members of the local community on lung cancer, prevention/risk reduction and smoking cessation. She also entertained questions from the audience on topics ranging from second-hand smoke exposure to the link between family history, genetics and lung cancer. Patricia Rich, MD Director, Lung Cancer Institute Vice Chief of Staff Director, Lung Cancer Center 10 CTCA Atlanta 2018 CANCER REGISTRY ANNUAL REPORT
Accreditations AND CERTIFICATIONS CTCA Atlanta is accredited and recognized by several renowned professional health care organizations that assess and monitor the quality of patient care. The Joint Commission The Joint Commission s Gold Seal of Approval for Hospital Accreditation reflects a commitment to providing safe and effective patient care and a willingness to voluntarily undergo rigorous, unannounced onsite surveys. Accreditation requires compliance with standards related to areas such as patient rights, environment of care, infection prevention, leadership and medication management. Quality Oncology Practice Initiative (QOPI) The QOPI Certification Program, an affiliate of the American Society of Clinical Oncology (ASCO), recognizes outpatient practices that meet the benchmarks for breast, colorectal, non-small cell lung, non-hodgkin lymphoma, gynecologic and prostate cancers. This seal designates those practices that scored high on key QOPI quality measures and met rigorous chemotherapy safety standards established by ASCO and the Oncology Nursing Society. Commission on Cancer (COC) The COC recognizes cancer care programs for their commitment to providing comprehensive, high-quality and multidisciplinary patient-centered care. COC Program Standards require facilities to create meaningful processes for implementation of patient-centered care. National Accreditation Program For Breast Cancers (NAPBC) Accreditation by the NAPBC is granted only to those centers that are voluntarily committed to providing the highest standards of care to patients with diseases of the breast. NAPBC requires a rigorous evaluation in a number of areas, including program leadership, use of evidence-based practices, surgery, imaging and quality improvement process. 11 CTCA Atlanta 2018 CANCER REGISTRY ANNUAL REPORT
About Cancer Treatment Centers of America Cancer Treatment Centers of America Global, Inc. (CTCA) is a comprehensive cancer care network of hospitals and outpatient care centers in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Specializing in the treatment of adult cancer patients, CTCA offers an integrative approach to care that combines surgery, radiation, chemotherapy, and immunotherapy with advancements in precision cancer treatment and supportive therapies designed to manage side effects and enhance quality of life both during and after treatment. CTCA also offers qualified patients a range of clinical trials that may reveal new treatment options supported by scientific and investigational research. CTCA patient satisfaction scores consistently rank among the highest for all cancer care providers in the country. HOSPITALS CTCA Atlanta CTCA Chicago CTCA Philadelphia CTCA Phoenix CTCA Tulsa OUTPATIENT CARE CENTERS Downtown Chicago North Phoenix Scottsdale Cancer Treatment Centers of America Atlanta 600 Celebrate Life Parkway Newnan, GA 30265 cancercenter.com 800-333-CTCA 2018 IPB